Phenotyping of Chronic Pain in Diffused Systemic Scleroderma
CompletedNot applicableNCT05622578
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The primary objective of the study is to describe the different phenotyping of pain in systemic scleroderma patients and perturbations of mechanisms of the pain. As secondary objectives, the study aims to describe the importances of overall symptoms in alteration of quality of life and conserve the questions which will be associated in a unique questionnaire in order to evaluate the pain, the fatigue and the sleeping disorders in diffused systemic scleroderma patients.
Study details
- Official title
- Phenotyping of Chronic Pain in Diffused Systemic Scleroderma: Characteristics and Perturbations of Mechanisms of Pain, Impact on the Quality of Life and Correlations of Fatigue, Sleeping Disorders and Mood or Anxiety Disorders
- Conditions
- Scleroderma, Systemic
- Scleroderma, Diffuse
- Interventions
- Other: QST, CPM and Paisudoscan
- Sponsor
- Assistance Publique - Hôpitaux de Paris
- Collaborators
- Association de patients : association sclérodermies de France
- Start date
- 2022-10-19
- Primary completion
- 2023-12-19
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- France
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Patients ≥ 18 years; * Patients with diffused SSc according to ACR / EULAR Classification 2013 since at least 3 months; * For group pain: pain intensity ≥4 of 11 points of scale (NRS); * For group painless: pain intensity on the month before inclusion. Exclusion Criteria: * Patients unable to understand french language; * Patients no-affiliated to the french social security scheme; * Patients under the french AME scheme; * Patients under guardianship; * Pregnant and breastfeeding patients; * Patients with thermoalgesic neuropathy; * Articular pain from degenerative diseases (known osteoarthritis); * Patients under antidepressant; * Temporary discontinuation of analgesics which are not well tolerated.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT05622578